Header

In the News

06 Feb 2011 | Reuters

Lionel Melka comments on the Sanofi-Genzyme deal

Genzyme, Sanofi boards meet to discuss deal

"Genzyme's share price was at $50 dollars several months ago, so a price of just below $80 is not bad at all, particularly because there are no other buyers," said Lionel Melka, co-manager of Bernheim, Dreyfus & Co's Diva Synergy Fund in Paris. Genzyme's stock traded at about $50 as recently as July, 2010. The stock closed Friday at $73.40.

31 Jan 2011 | Reuters

Lionel Melka comments on the Sanofi-Genzyme deal

Genzyme and Sanofi agree on deal outline

"If Genzyme is opening its books to Sanofi, it means that there is an agreement on price, or at least a very narrow range subject to adjustment following due diligence findings," said Lionel Melka, co-manager of Bernheim, Dreyfus & Co's Diva Synergy Fund, which owns Genzyme shares.

21 Jan 2011 | Reuters

Lionel Melka comments on the Sanofi-Genzyme deal

Sanofi must tread carefully in Genzyme endgame

"Genzyme has no other option, no white knight and disappointing results so I am not sure that their negotiation position is so strong," said Lionel Melka, co-manager of the Bernheim, Dreyfus & Co Diva Synergy Fund.

19 Jan 2011 | Reuters

Lionel Melka comments on the Sanofi-Genzyme deal

PREVIEW-Sanofi seen extending Genzyme tender as talks progress

"We believe we are approaching a happy end. We think that Sanofi will extend one more time to take time to seal the deal," said Lionel Melka, co-manager of Bernheim, Dreyfus & Co's Diva Synergy Fund which owns Genzyme shares.

10 11 12 13 14 15 16 17 18 19 20 |  21 |  22 23 24 25 26 27 28 29 30 31 32 33 34